Biological Significance of Anti–SARS-CoV-2 Antibodies
Lessons Learned From Progressive Multifocal Leukoencephalopathy
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received August 13, 2020
- Accepted in final form November 9, 2020
- First Published December 24, 2020.
Author Disclosures
- Navid Manouchehri, MD (navid.manouchehriardestani{at}utsouthwestern.edu),
- Lawrence Steinman, MD (steiny{at}stanford.edu) and
- Olaf Stuve, MD, PhD
- Navid Manouchehri, MD (navid.manouchehriardestani{at}utsouthwestern.edu),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lawrence Steinman, MD (steiny{at}stanford.edu) and
Novartis, Atreca, Tolerion, Teva, AbbVie, Bristol Myers Squibb, Gossamer, 180LS, TG Therapeutics, Atara Bio
NONE
Novartis, Atara Bio
MS Journal, Proceedings National Academy of Sciences
I have a patent pending on cytokines and type 1 interferons. I have multiple patents on antigen specific tolerance.
NONE
NONE
Commercial Novartis, Atreca, Tolerion, Teva, AbbVie, Bristol Myers Squibb, Gossamer, 180LS, TG Therapeutics, Atara Bio
NONE
NONE
NONE
Atara Bio, Novartis
NIH 2U01AI101984-06 Cooperative Study Group for Autoimmune Disease Prevention (U01)
NONE
NONE
Stock options and board membership in Tolerion, Atreca Board of Directors BioAtla
NONE
Tolerion Stock/Stock Options, Medical Equipment & Materials: Tolerion, Atreca, Adaptive
NONE
NONE
NONE
- Olaf Stuve, MD, PhD
TG Therapeutics, Genentech-Roche, EMD Serono, Celgene, Genzyme
NONE
NONE
Therapeutic Advances in Neurological Disorders
PCT/US2019/020380
NONE
NONE
Celgene EMD Serono Novartis
NONE
NONE
NONE
Sanofi Genzyme, EMD Serono
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (N.M.), the University of Texas Southwestern Medical Center, Dallas; Departments of Pediatrics and Neurology and Neurological Sciences (L.S.), Stanford University, CA; and Neurology Section (O.S.), VA North Texas Health Care System, Medical Service Dallas, VA Medical Center.
- Correspondence
Dr. Stuve olaf.stuve{at}utsouthwestern.edu
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Daniel Friedman and Dr. Sharon Chiang
► Watch
Related Articles
- No related articles found.